Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103 and FDX104. Its lead product candidate, FMX101, is a topical foam formulation of the antibiotic minocycline for the treatment of moderate-to-severe acne. FMX102 is a formulation of its minocycline foam being developed for the treatment of impetigo. FMX103 is a topical foam formulation of minocycline for the treatment of moderate-to-severe Papulopustular rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It has conducted one Phase II clinical trial for each of FMX101, FMX102, FMX103 and FDX104.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:FOMX
- CUSIP: N/A
- Web: www.foamixpharma.com
- Market Cap: $168.25 million
- Outstanding Shares: 37,223,000
- 50 Day Moving Avg: $4.48
- 200 Day Moving Avg: $8.32
- 52 Week Range: $4.03 - $11.27
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.65
- P/E Growth: 0.00
- Annual Revenue: $5.71 million
- Price / Sales: 29.47
- Book Value: $3.13 per share
- Price / Book: 1.44
- EBIDTA: ($39,500,000.00)
- Net Margins: -554.14%
- Return on Equity: -22.55%
- Return on Assets: -21.59%
- Current Ratio: 18.90%
- Quick Ratio: 18.90%
- Average Volume: 316,992 shs.
- Beta: 1.62
- Short Ratio: 8.08
Frequently Asked Questions for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
What is Foamix Pharmaceuticals Ltd's stock symbol?
Foamix Pharmaceuticals Ltd trades on the NASDAQ under the ticker symbol "FOMX."
How were Foamix Pharmaceuticals Ltd's earnings last quarter?
Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) posted its quarterly earnings data on Wednesday, August, 10th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.25) by $0.02. The business earned $1.50 million during the quarter, compared to the consensus estimate of $1.10 million. Foamix Pharmaceuticals Ltd had a negative net margin of 554.14% and a negative return on equity of 22.55%. View Foamix Pharmaceuticals Ltd's Earnings History.
Where is Foamix Pharmaceuticals Ltd's stock going? Where will Foamix Pharmaceuticals Ltd's stock price be in 2017?
2 brokerages have issued 1-year price objectives for Foamix Pharmaceuticals Ltd's stock. Their predictions range from $9.00 to $20.00. On average, they anticipate Foamix Pharmaceuticals Ltd's share price to reach $14.50 in the next twelve months. View Analyst Ratings for Foamix Pharmaceuticals Ltd.
Who are some of Foamix Pharmaceuticals Ltd's key competitors?
Some companies that are related to Foamix Pharmaceuticals Ltd include GlycoMimetics (GLYC), Concert Pharmaceuticals (CNCE), Edge Therapeutics (EDGE), Ocular Therapeutix (OCUL), XBiotech (XBIT), Novavax (NVAX), Ignyta (RXDX), Veracyte (VCYT), SIGA Technologies (SIGA), Dynavax Technologies (DVAX), Nabriva Therapeutics AG - (NBRV), Compugen (CGEN), Minerva Neurosciences (NERV), Ardelyx (ARDX), Sinovac Biotech (SVA), Kamada Ltd (KMDA), Akebia Therapeutics (AKBA) and Idera Pharmaceuticals (IDRA).
Who owns Foamix Pharmaceuticals Ltd stock?
Foamix Pharmaceuticals Ltd's stock is owned by many different of retail and institutional investors. Top institutional shareholders include RA Capital Management LLC (4.90%), Perceptive Advisors LLC (3.56%), Tekla Capital Management LLC (2.50%), AXA (2.22%), OppenheimerFunds Inc. (1.48%) and MARSHALL WACE ASIA Ltd (1.19%). View Institutional Ownership Trends for Foamix Pharmaceuticals Ltd.
Who sold Foamix Pharmaceuticals Ltd stock? Who is selling Foamix Pharmaceuticals Ltd stock?
Foamix Pharmaceuticals Ltd's stock was sold by a variety of institutional investors in the last quarter, including Menora Mivtachim Holdings LTD., Driehaus Capital Management LLC, OppenheimerFunds Inc., Bank of New York Mellon Corp, Sphera Funds Management LTD., Menta Capital LLC and UBS Asset Management Americas Inc.. View Insider Buying and Selling for Foamix Pharmaceuticals Ltd.
Who bought Foamix Pharmaceuticals Ltd stock? Who is buying Foamix Pharmaceuticals Ltd stock?
Foamix Pharmaceuticals Ltd's stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., MARSHALL WACE ASIA Ltd, Jennison Associates LLC, Emory University, AXA, Goldman Sachs Group Inc., Renaissance Technologies LLC and Baird Financial Group Inc.. View Insider Buying and Selling for Foamix Pharmaceuticals Ltd.
How do I buy Foamix Pharmaceuticals Ltd stock?
Shares of Foamix Pharmaceuticals Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Foamix Pharmaceuticals Ltd stock cost?
One share of Foamix Pharmaceuticals Ltd stock can currently be purchased for approximately $4.52.
Consensus Ratings for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||2 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$14.50 (220.80% upside)|
Analysts' Ratings History for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
(Data available from 5/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|3/28/2017||Credit Suisse Group AG||Lower Price Target||Outperform||$22.00 -> $9.00||High|
|8/13/2016||Guggenheim||Reiterated Rating||Buy||$10.00 -> $20.00||N/A|
Earnings History for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)Earnings History by Quarter for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/10/2016||Q216||($0.25)||($0.27)||$1.10 million||$1.50 million||View||Listen|
|5/10/2016||Q1||($0.23)||($0.15)||$0.53 million||$0.75 million||View||Listen|
|11/11/2015||Q315||($0.20)||($0.11)||$1.50 million||$0.02 million||View||Listen|
|8/19/2015||Q215||($0.14)||($0.18)||$1.00 million||$0.11 million||View||Listen|
|5/12/2015||Q1||($0.12)||($0.14)||$1.00 million||$0.45 million||View||N/A|
|11/14/2014||Q314||($0.07)||($0.12)||$1.00 million||$0.42 million||View||N/A|
Earnings Estimates for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
Current Year EPS Consensus Estimate: $-1.59 EPS
Next Year EPS Consensus Estimate: $-0.80 EPS
Dividend History for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
Latest Headlines for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
Foamix Pharmaceuticals Ltd (FOMX) Chart for Wednesday, May, 24, 2017